MCID: NRN004
MIFTS: 55

Neuroendocrine Tumor

Categories: Cancer diseases, Endocrine diseases, Neuronal diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Neuroendocrine Tumor

MalaCards integrated aliases for Neuroendocrine Tumor:

Name: Neuroendocrine Tumor 12 74 52 15
Neuroendocrine Neoplasm 12 52 58 29 6 17
Neuroendocrine Tumors 54 43 15 71
Carcinoma, Neuroendocrine 71
Neuroendocrine Neoplasia 52

Characteristics:

Orphanet epidemiological data:

58
neuroendocrine neoplasm
Prevalence: 1-9/100000 (United States),1-9/100000 (Europe); Age of onset: Adult;

Classifications:

Orphanet: 58  
Rare endocrine diseases


External Ids:

Disease Ontology 12 DOID:169
ICD9CM 34 209-209.99
MeSH 43 D018358
NCIt 49 C3809
SNOMED-CT 67 255046005 55937004
ICD10 32 D3A.8
UMLS via Orphanet 72 C0003650 C0014132 C0206754
Orphanet 58 ORPHA877
UMLS 71 C0206695 C0206754

Summaries for Neuroendocrine Tumor

NIH Rare Diseases : 52 A neuroendocrine tumor (NET) is a rare type of tumor that arises from specialized body cells called neuroendocrine cells . These cells have traits of both nerve cells and hormone -producing cells, and release hormones into the blood in response to signals from the nervous system. Because a neuroendocrine tumor arises from cells that produce hormones, the tumor can also produce hormones. Neuroendocrine tumors can develop anywhere in the body, but most occur in the digestive tract, pancreas, rectum, lungs, or appendix. They can be non-cancerous (benign) or cancerous (malignant). They usually grow slowly over many years, but there are fast-growing forms. There are many types of neuroendocrine tumors, but most are classified as one of two main types: Carcinoid tumors - NETs that most commonly arise in the digestive tract, lungs, appendix or thymus. They can also grow in the lymph nodes , brain, bone, gonads (ovaries and testes ) or skin. Pancreatic neuroendocrine tumors (also called islet cell tumors) - NETs that typically arise in the pancreas, although they can occur outside the pancreas. A p heochromocytoma is another, rarer type of NET that usually develops in the adrenal gland , but can also arise in other parts of the body. Signs and symptoms depend on the tumor's type, size and location; whether it produces hormones; and whether it has spread to other parts of the body (metastasized). NETs are typically described as functional or nonfunctional. Functional NETs produce a specific set of symptoms due to the production of excess hormones, while non-functional NETs generally do not cause specific symptoms. In many cases, a person has no symptoms until the tumor spreads to the liver and/or impairs the function of an organ or system. This can make NETs very hard to diagnose. The majority of NETs are not inherited and occur sporadically in people with no family history of NETs. However, some NETs are associated with a hereditary cancer or tumor syndrome such as multiple endocrine neoplasia type 1 (most commonly), Von Hippel-Lindau disease , tuberous sclerosis , or neurofibromatosis type 1 (NF1). Inheritance of each of these is autosomal dominant . Treatment of NETs depends on many factors such as the tumor's type, location, aggressiveness, and hormone-producing capabilities; as well as whether it has metastasized. Management options may include surveillance, surgery to remove the tumor and/or surrounding tissue , and various non-surgical therapies to shrink the tumor, stop it from growing, or manage symptoms.

MalaCards based summary : Neuroendocrine Tumor, also known as neuroendocrine neoplasm, is related to esophageal neuroendocrine tumor and laryngeal neuroendocrine tumor. An important gene associated with Neuroendocrine Tumor is MEN1 (Menin 1), and among its related pathways/superpathways are Neuroscience and Neural Stem Cells and Lineage-specific Markers. The drugs Bromocriptine and Thrombin have been mentioned in the context of this disorder. Affiliated tissues include liver, lung and thyroid, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Disease Ontology : 12 An endocrine gland cancer that has material basis in neuroendocrine cells.

Wikipedia : 74 Neuroendocrine tumors (NETs) are neoplasms that arise from cells of the endocrine (hormonal) and nervous... more...

Related Diseases for Neuroendocrine Tumor

Diseases related to Neuroendocrine Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 828)
# Related Disease Score Top Affiliating Genes
1 esophageal neuroendocrine tumor 34.6 SYP NCAM1 CHGA
2 laryngeal neuroendocrine tumor 34.5 SYP NCAM1 CHGA CALCA
3 anal neuroendocrine tumor 34.4 SYP SST NCAM1 ENO2
4 gastrointestinal neuroendocrine tumor 34.4 SYP SSTR2 SST MEN1 GAST CHGA
5 pulmonary neuroendocrine tumor 34.3 SYP SSTR2 SST NCAM1 MEN1 ENO2
6 islet cell tumor 34.0 SYP SSTR2 SST MEN1 GAST ENO2
7 rectum neuroendocrine neoplasm 33.7 SYP SST GAST
8 small intestine neuroendocrine neoplasm 33.6 SST MEN1
9 gastric neuroendocrine neoplasm 33.6 SYP SST MEN1 GAST CHGA
10 von hippel-lindau syndrome 33.5 SDHD MEN1 CHGB CHGA
11 insulinoma 33.5 SSTR2 SST MEN1 INSM1 GAST CHGA
12 goblet cell carcinoid 33.3 GAST ENO2 CHGA
13 glucagonoma 33.3 SST GAST CHGB CHGA
14 breast neuroendocrine neoplasm 33.3 SYP ENO2 CHGA
15 duodenal gastrinoma 33.2 SST MEN1 GAST CHGA
16 prostate neuroendocrine neoplasm 33.1 SYP NCAM1 ENO2 CHGA
17 vipoma 33.0 SST NTS MEN1 GAST CHGA CALCA
18 gastrinoma 33.0 SYP SSTR2 SST MEN1 GRP GAST
19 colon neuroendocrine neoplasm 32.9 SYP NCAM1 ENO2 CHGA CALCA
20 duodenal somatostatinoma 32.7 SST MEN1
21 gastric gastrinoma 32.7 MEN1 GAST ENO2 CHGA
22 pancreatic cancer 32.5 SSTR2 SST NTS MTOR MEN1 GRP
23 neuroendocrine carcinoma 32.4 SYP SST SCG2 NCAM1 MEN1 GRP
24 adrenal carcinoma 32.4 SYP SST SDHD MEN1 ENO2 CHGA
25 multiple endocrine neoplasia, type i 31.8 SYP SST SDHD MEN1 GAST CHGA
26 zollinger-ellison syndrome 31.7 SST NTS MEN1 GRP GAST CHGA
27 large cell neuroendocrine carcinoma 31.7 SYP NCAM1 ENO2 CHGA ASCL1
28 atrophic gastritis 31.6 SST MEN1 GAST CHGA
29 adenoma 31.6 SYP SSTR2 SST MKI67 MEN1 CHGA
30 carcinoid syndrome 31.5 SYP SST SDHD NTS MEN1 ENO2
31 acromegaly 31.5 SSTR2 SST MEN1 CCK
32 thyroid gland medullary carcinoma 31.5 SSTR2 SST MEN1 GAST CHGA CALCA
33 hyperparathyroidism 31.3 MEN1 GAST CHGA CALCA
34 conn's syndrome 31.3 SST MEN1 CHGA CALCA
35 diarrhea 31.3 SST NTS MEN1 GAST CCK CALCA
36 teratoma 31.2 SYP SST ENO2 CHGA
37 small cell carcinoma 31.2 SYP NCAM1 INSM1 GRP GAST ENO2
38 acinar cell carcinoma 31.2 SYP GAST CHGA
39 tuberous sclerosis 31.2 SYP SST MTOR ENO2 CHGA
40 pernicious anemia 31.2 SST GAST CHGA
41 serotonin syndrome 31.2 SST MEN1 GAST CHGA
42 primary hyperparathyroidism 31.2 MEN1 GAST CHGA CALCA
43 autoimmune atrophic gastritis 31.1 GAST CHGA
44 carcinoid tumors, intestinal 31.1 SYP SSTR2 SST MEN1 GAST ENO2
45 hyperinsulinemic hypoglycemia 31.1 SST MEN1 ENO2
46 merkel cell carcinoma 31.0 SYP SST NCAM1 ENO2 CHGA
47 peptic ulcer disease 31.0 SST MEN1 GRP GAST
48 parathyroid adenoma 31.0 MEN1 GAST CHGB CHGA CALCA
49 pituitary adenoma 31.0 SSTR2 SST SCG2 MEN1 CHGB CHGA
50 hemangioma 31.0 SYP MTOR MEN1 ENO2 CHGA

Graphical network of the top 20 diseases related to Neuroendocrine Tumor:



Diseases related to Neuroendocrine Tumor

Symptoms & Phenotypes for Neuroendocrine Tumor

GenomeRNAi Phenotypes related to Neuroendocrine Tumor according to GeneCards Suite gene sharing:

26 (show all 35)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-11 10.03 MTOR
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-111 10.03 SSTR2
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-123 10.03 CHGA
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-16 10.03 MTOR
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-164 10.03 SSTR2
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 10.03 MTOR SDHD
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-174 10.03 CHGA
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-176 10.03 CHGA
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 10.03 SSTR2
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-215 10.03 CHGA
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.03 SDHD
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-42 10.03 MTOR
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-52 10.03 SSTR2
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.03 MTOR SDHD SSTR2
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-56 10.03 SSTR2
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-61 10.03 CHGA
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-70 10.03 CHGA
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-73 10.03 MTOR
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-81 10.03 SDHD
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 10.03 INSM1
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 10.03 SSTR2
22 Decreased viability GR00055-A-1 9.75 MTOR NCAM1
23 Decreased viability GR00055-A-2 9.75 MTOR
24 Decreased viability GR00106-A-0 9.75 MEN1
25 Decreased viability GR00221-A-1 9.75 MTOR SDHD
26 Decreased viability GR00221-A-2 9.75 SDHD
27 Decreased viability GR00221-A-4 9.75 MTOR SDHD
28 Decreased viability GR00240-S-1 9.75 SST
29 Decreased viability GR00249-S 9.75 INSM1 MKI67 SDHD SSTR2
30 Decreased viability GR00342-S-1 9.75 MTOR
31 Decreased viability GR00342-S-2 9.75 MTOR
32 Decreased viability GR00381-A-1 9.75 CALCA GRP SDHD
33 Decreased viability GR00381-A-3 9.75 GRP
34 Decreased viability GR00386-A-1 9.75 CCK GRP MKI67 SCG2 SYP
35 Decreased viability GR00402-S-2 9.75 ENO2 GRP

MGI Mouse Phenotypes related to Neuroendocrine Tumor:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.83 ASCL1 CCK CHGA CHGB ENO2 GRP
2 endocrine/exocrine gland MP:0005379 9.81 ASCL1 CCK CHGA CHGB GAST INSM1
3 no phenotypic analysis MP:0003012 9.28 ASCL1 CCK CHGA CHGB INSM1 MKI67

Drugs & Therapeutics for Neuroendocrine Tumor

Drugs for Neuroendocrine Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 292)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
2
Thrombin Approved, Investigational Phase 4
3
Glycolic acid Approved, Investigational Phase 4 79-14-1 757
4
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
5
Cabergoline Approved Phase 4 81409-90-7 54746
6
Pancrelipase Approved, Investigational Phase 4 53608-75-6
7 Hemostatics Phase 4
8 Dopamine agonists Phase 4
9 Antiparkinson Agents Phase 4
10 pancreatin Phase 4
11 Chelating Agents Phase 4
12 Gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate Phase 4
13
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
14
Streptozocin Approved, Investigational Phase 3 18883-66-4 29327
15
Axitinib Approved, Investigational Phase 2, Phase 3 319460-85-0 6450551
16
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
17
leucovorin Approved Phase 2, Phase 3 58-05-9 6006 143
18
Oxaliplatin Approved, Investigational Phase 2, Phase 3 61825-94-3 43805 6857599 5310940 9887054
19
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
20
Levoleucovorin Approved, Investigational Phase 2, Phase 3 68538-85-2
21
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
22 Pancreatic Polypeptide Investigational Phase 2, Phase 3 59763-91-6
23 Liver Extracts Phase 2, Phase 3
24 Edotreotide Phase 3
25 Radiopharmaceuticals Phase 3
26 lysine Phase 3
27 Antineoplastic Agents, Hormonal Phase 3
28 Gastrointestinal Agents Phase 3
29 Immunoglobulins, Intravenous Phase 3
30 Immunoglobulin G Phase 3
31 Calcium, Dietary Phase 3
32 Antimetabolites Phase 2, Phase 3
33 Angiogenesis Inhibitors Phase 2, Phase 3
34 Protective Agents Phase 2, Phase 3
35 Trace Elements Phase 2, Phase 3
36 Vitamins Phase 2, Phase 3
37 Vitamin B Complex Phase 2, Phase 3
38 Nutrients Phase 2, Phase 3
39 Micronutrients Phase 2, Phase 3
40 Folate Phase 2, Phase 3
41 Vitamin B9 Phase 2, Phase 3
42 Antidotes Phase 2, Phase 3
43 5-hydroxytryptophan Phase 3
44 Serotonin Receptor Agonists Phase 3
45
Arginine Investigational, Nutraceutical Phase 3 74-79-3 6322
46
Calcium Nutraceutical Phase 3 7440-70-2 271
47
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
48
Tegafur Approved, Investigational Phase 2 17902-23-7 5386
49
Metformin Approved Phase 2 657-24-9 14219 4091
50
Loperamide Approved Phase 1, Phase 2 53179-11-6 3955

Interventional clinical trials:

(show top 50) (show all 665)
# Name Status NCT ID Phase Drugs
1 Dual Tracer Functional Imaging of Nonfunctional Pancreatic Neuroendocrine Tumors Using 68Ga-DOTA-NOC and 18F-FDG PET/CT Unknown status NCT02621541 Phase 4
2 Clinical Effectiveness of Serum Chromogranin A (CgA) Levels on Diagnostic Relevance, Response After Surgical Resection and Recurrence of Pancreatic Endocrine Tumors (PET) Unknown status NCT02759718 Phase 4
3 The Use of Lu177 in the Treatment of Progressive and Unresectable Metastatic Medullary Thyroid Cancer Unknown status NCT01915485 Phase 4
4 The Therapeutic Effect of Bromocriptin in Patients With Primary Aldosteronism Unknown status NCT00451672 Phase 4 bromocriptine
5 A SINGLE-ARM OPEN-LABEL INTERNATIONAL MULTI-CENTER STUDY OF THE EFFICACY AND SAFETY OF SUNITINIB MALATE (SU011248, SUTENT (REGISTERED)) IN PATIENTS WITH PROGRESSIVE ADVANCED METASTATIC WELL-DIFFERENTIATED UNRESECTABLE PANCREATIC NEUROENDOCRINE TUMORS Completed NCT01525550 Phase 4 sunitinib
6 An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1) Completed NCT01595009 Phase 4 Everolimus (RAD001)
7 A Multi-centric, Open-label, Phase II Study Investigating the Combination of Afinitor With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced (Stage IV) Large Cell Lung Cancer With Neuroendocrine Differentiation (LC-NEC) Completed NCT01317615 Phase 4 RAD001;Paclitaxel;Carboplatin
8 A Phase IV, International, Open-label, Randomised, Cross-over Study to Assess Patient Preference and Health Economy in Patients With Neuroendocrine Tumours, Treated With Lanreotide Autogel Given as Self Administration. Completed NCT00681187 Phase 4 lanreotide (Autogel formulation)
9 A Phase IV, Multicentre, Open Label, Single Group Exploratory Study to Assess the Clinical Value of Enumeration of Circulating Tumour Cells (CTCs) to Predict Clinical Symptomatic Response and Progression Free Survival in Patients Receiving Deep Subcutaneous Administrations of Somatuline® (Lanreotide) Autogel® to Treat the Symptoms of Functioning Midgut NeuroEndocrine Tumours (NET) Completed NCT02075606 Phase 4 lanreotide acetate
10 Use of Polyethylene Glycolic Acid or Tachocomb to Prevent Pancreatic Fistula Following Distal Pancreatectomy: Prospective Multicenter Randomized Study Completed NCT01550406 Phase 4
11 A Pilot Study To Evaluate Patient Experience With the Somatostatin Analogs Octreotide Long Acting Release and Lanreotide During the Treatment of Advanced, Nonfunctional, Well Differentiated Neuroendocrine Tumors Recruiting NCT03289741 Phase 4 Octreotide;LAR Lanreotide
12 PILOT STUDY OF LANREOTIDE IN METASTATIC OR RECURRENT GRADE I-II HINDGUT NET Recruiting NCT03083210 Phase 4 Lanreotide
13 A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to a 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients Recruiting NCT01896479 Phase 4 Cabozantinib (XL184) 140 mg;Cabozantinib (XL184) 60 mg;Placebo tablet;Placebo capsule
14 An Open-label, Multi-center Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study and Are Judged by the Investigator to Benefit From Continued Everolimus Treatment Recruiting NCT01789281 Phase 4 Everolimus;Sandostatin LAR Depot
15 Phase IV, Open-label, Multi-center, Single-arm Study of the Safety and Efficacy of Everolimus (Afinitor) in Adult Patients With Local Advanced or Metastatic, Well Differentiated Progressive Pancreatic Neuroendocrine Tumors (pNET) in China. Active, not recruiting NCT02842749 Phase 4 everolimus
16 An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment Active, not recruiting NCT01794793 Phase 4 Pasireotide;Cabergoline;Pasireotide
17 Prospective Evaluation of Potential Effects of Repeated Gadolinium-based Contrast Agent (GBCA) Administrations of the Same GBCA on Motor and Cognitive Functions in Neurologically Normal Adults in Comparison to a Non-GBCA Exposed Control Group Not yet recruiting NCT04373564 Phase 4 Gadoxetate disodium;Gadobenate dimeglumine;Gadodiamide;Gadoterate meglumine;Gadobutrol;Gadoteridol
18 Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation A Prospective Interventional Trial of Patients With Neuro-endocrine Tumors With Carcinoid Syndrome Receiving Octreotide LAR Terminated NCT04140409 Phase 4 Sandostatin
19 Pasireotide Treatment for Insulin Producing Pancreatic Neuro-endocrine Tumor Withdrawn NCT02779257 Phase 4 Pasireotide;Diazoxide
20 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3 123I-meta-iodobenzylguanidine
21 Impact of [68 Ga]-DOTANOC PET-CT on the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Prospective, Multicentric Study. Unknown status NCT02608203 Phase 2, Phase 3 [68Ga]-DOTANOC PET/CT
22 Study to Investigate the Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut Completed NCT00171873 Phase 3 Octreotide LAR (Long-acting release);Placebo
23 A Randomized Double-blind Phase III Study of RAD001 10 mg/d Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Neuroendocrine Tumor (NET) Completed NCT00510068 Phase 3 Everolimus;Everolimus Placebo
24 High Dose Indium-111 Pentetreotide Therapy in Somatostatin Receptor Expressing Neuroendocrine Neoplasms. Completed NCT00442533 Phase 2, Phase 3 Indium-111 pentetreotide
25 Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan Completed NCT03136328 Phase 3 68Ga-DOTATOC
26 High Dose I-131 Metaiodobenzylguanidine (MIBG) Therapy for Metastatic Neuroendocrine Tumors Completed NCT00037869 Phase 3 I-131 Metaiodobenzylguanidine
27 An Open-label, Single-dose, Single Arm, Single-center Clinical Trial of 64Cu-DOTATATE (NETMedix™) PET-CT Scan for Imaging Patients With Known or Suspected Somatostatin Receptor-positive Neuroendocrine Tumors (NETs) Completed NCT03673943 Phase 3 64Cu-DOTATATE
28 A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With Medullary Thyroid Carcinoma(ALTER01031) Completed NCT02586350 Phase 2, Phase 3 Anlotinib;Placebo
29 A EUROPEAN, MULTICENTRE, PHASE II/III RANDOMISED DOUBLE-BLIND, PLACEBO CONTROLLED STUDY EVALUATING LANREOTIDE AS MAINTENANCE THERAPY IN PATIENTS WITH NON-RESECTABLE DUODENO-PANCREATIC NEUROENDOCRINE TUMOURS AFTER FIRST-LINE TREATMENT Completed NCT02288377 Phase 2, Phase 3 lanreotide;Placebo
30 A Double Blind, Randomized Placebo Controlled Clinical Trial Investigating the Efficacy and Safety of Somatuline Depot (Lanreotide) Injection in the Treatment of Carcinoid Syndrome Completed NCT00774930 Phase 3 Lanreotide;Placebo
31 Treatment of Advanced Hepatocellular Carcinoma With Depot Somatostatin Analogues: a Pilot Prospective Study Based on Somatostatin Receptors Tumors Expression Completed NCT00495846 Phase 2, Phase 3 Octreotide-LAR, Lanreotide Autogel
32 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety Recruiting NCT03042416 Phase 3 18F-DOPA
33 A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET Recruiting NCT03972488 Phase 3 Lutathera;long-acting octreotide;high dose long-acting octreotide
34 Intra-arterial Lutetium-177-dotatate for Treatment of Patients With Neuro-endocrine Tumor Liver Metastases Recruiting NCT03590119 Phase 2, Phase 3 Lutetium Lu 177-DOTATATE
35 The LuMEn Study: 177Lu-octreotate Treatment Outcome Prediction Using Multimodality Imaging in Refractory Neuroendocrine Tumours. Recruiting NCT01842165 Phase 3 Intravenous injection of 177Lu-octreotate
36 A Prospective, Randomised, Controlled, Open-label, Multicentre Phase III Study to Evaluate Efficacy and Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-Edotreotide Compared to Targeted Molecular Therapy With Everolimus in Patients With Inoperable, Progressive, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumours of Gastroenteric or Pancreatic Origin (GEP-NET) Recruiting NCT03049189 Phase 3 177Lu-edotreotide PRRT;Everolimus
37 Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Everolimus (CABINET) Recruiting NCT03375320 Phase 3 Cabozantinib S-malate
38 A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531) Recruiting NCT04211337 Phase 3 Selpercatinib;Cabozantinib;Vandetanib
39 Phase II/III Trial of Simmtecan and 5-FU/LV Regimen (FOLFSIM) Plus Teripalimab Versus EP/EC in Advanced or Metastatic Neuroendocrine Carcinoma Recruiting NCT03992911 Phase 2, Phase 3 Simmtecan, 5-FU and l-LV;Toripalimab;Etoposide, Cisplatin;Etoposide, Carboplatin
40 Ga-68-DOTATOC -PET in the Management of Pituitary Tumours Recruiting NCT02419664 Phase 3
41 A Randomized, Double-blind, Multicenter, Phase III Study of Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced NET of GI or Lung Origin Active, not recruiting NCT01524783 Phase 3 Everolimus;Everolimus Placebo
42 Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients Active, not recruiting NCT00569127 Phase 3 Octreotide Acetate
43 A Randomized, Double-blind, Multi-center Phase III Clinical Study to Assess the Efficacy and Safety of Surufatinib Compared to Placebo in Patients With Advanced Pancreatic Neuroendocrine Tumors Active, not recruiting NCT02589821 Phase 3 Surufatinib
44 A Randomized, Double-blind, Multi-center Phase III Clinical Study to Assess the Efficacy and Safety of Surufatinib Compared to Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors Active, not recruiting NCT02588170 Phase 3 Surufatinib
45 A Phase II/III Randomized Double-blind Study of Sandostatin LAR in Combination With Axitinib Versus Sandostatin LAR With Placebo in Patients With Advanced G1-G2 Neuroendocrine Tumours (WHO 2010) of Non-pancreatic Origin Active, not recruiting NCT01744249 Phase 2, Phase 3 Axitinib;Sandostatin LAR;Placebo
46 An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer Active, not recruiting NCT00410761 Phase 3 ZD6474 (Vandetanib)
47 A Randomized,Int.,Open-Label Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients With Locally Advanced or Metastatic MTC Experience Grade 2 or Higher AEs in the First 12 Months of Treatment With Vandetanib Active, not recruiting NCT01298323 Phase 3 Vandetanib
48 A Phase 3, Prospective, Randomized, Double-blind, Multi-center Study of the Efficacy and Safety of Lanreotide Autogel/Depot 120 mg Plus BSC vs. Placebo Plus BSC for Tumor Control in Subjects With Well Differentiated, Metastatic and/or Unresectable, Typical or Atypical, Lung Neuroendocrine Tumors Active, not recruiting NCT02683941 Phase 3 Lanreotide (Autogel formulation);Placebo
49 Randomized Open Label Study to Compare the Efficacy and Safety of Everolimus Followed by Chemotherapy With Streptozotocin- Fluorouracilo (STZ-5FU) Upon Progression or the Reverse Sequence, in Advanced Progressive Pancreatic NETs (pNETs) Active, not recruiting NCT02246127 Phase 3 Drug: Everolimus;STZ-5FU
50 A Multicentre, Stratified, Open, Randomized, Comparator-controlled, Parallel-group Phase III Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours Active, not recruiting NCT01578239 Phase 3 Octreotide LAR;177Lu-DOTA0-Tyr3-Octreotate

Search NIH Clinical Center for Neuroendocrine Tumor

Inferred drug relations via UMLS 71 / NDF-RT 50 :


lanreotide
sunitinib
sunitinib malate

Cochrane evidence based reviews: neuroendocrine tumors

Genetic Tests for Neuroendocrine Tumor

Genetic tests related to Neuroendocrine Tumor:

# Genetic test Affiliating Genes
1 Neuroendocrine Neoplasm 29

Anatomical Context for Neuroendocrine Tumor

MalaCards organs/tissues related to Neuroendocrine Tumor:

40
Liver, Lung, Thyroid, Pancreas, Lymph Node, Prostate, Breast

Publications for Neuroendocrine Tumor

Articles related to Neuroendocrine Tumor:

(show top 50) (show all 4872)
# Title Authors PMID Year
1
The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells. 61 54
19815051 2010
2
PACAP induces signaling and stimulation of 5-hydroxytryptamine release and growth in neuroendocrine tumor cells. 61 54
19701709 2009
3
Stimulatory effect of growth hormone-releasing hormone (GHRH(1-29)NH2) on the proliferation, VEGF and chromogranin A secretion by human neuroendocrine tumor cell line NCI-H727 in vitro. 61 54
19747727 2009
4
Chromogranin-A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor. 61 54
19667278 2009
5
[Chromogranin A (CgA) - characteristic of the currently available laboratory methods and conditions which can influence the results]. 54 61
19885814 2009
6
Thyroid metastases from typical carcinoid of the lung differentiating between medullary thyroid carcinoma and neuroendocrine tumor metastasis to the thyroid. 61 54
19415998 2009
7
Combination therapy with histone deacetylase inhibitors and lithium chloride: a novel treatment for carcinoid tumors. 61 54
19030935 2009
8
Hypoglycemia induced by long-acting somatostatin analogues in a patient with nonfunctional neuroendocrine tumor. 61 54
19365885 2009
9
Role of menin in neuroendocrine tumorigenesis. 61 54
20175456 2009
10
Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer. 54 61
19115997 2008
11
Curative resection of primary hepatic gastrinoma. 61 54
19260510 2008
12
Suberoyl bishydroxamic acid activates notch1 signaling and suppresses tumor progression in an animal model of medullary thyroid carcinoma. 54 61
18563491 2008
13
Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines. 61 54
18618499 2008
14
An overview of practical issues in the diagnosis of gastroenteropancreatic neuroendocrine pathology. 54 61
18684027 2008
15
Valproic acid induces Notch1 signaling in small cell lung cancer cells. 54 61
18570928 2008
16
The effect of transforming growth factor beta on human neuroendocrine tumor BON cell proliferation and differentiation is mediated through somatostatin signaling. 61 54
18567806 2008
17
Valproic acid activates Notch1 signaling and induces apoptosis in medullary thyroid cancer cells. 61 54
18520232 2008
18
Surgical treatment of a rare primary renal carcinoid tumor with liver metastasis. 61 54
18430248 2008
19
Elevated cocaine- and amphetamine-regulated transcript immunoreactivity in the circulation of patients with neuroendocrine malignancy. 54 61
18211969 2008
20
Update: improvement strategies for peptide receptor scintigraphy and radionuclide therapy. 61 54
18454684 2008
21
Nuclear medicine procedures in the diagnosis and therapy of medullary thyroid carcinoma. 61 54
17892924 2008
22
Suberoyl bishydroxamic acid inhibits cellular proliferation by inducing cell cycle arrest in carcinoid cancer cells. 54 61
17874277 2007
23
[Diagnostic procedures and more particularly, place of scintigraphy in neuroendocrine tumors, example of vipoma in MEN 1]. 61 54
17292846 2007
24
SOCS1 silencing enhances antitumor activity of type I IFNs by regulating apoptosis in neuroendocrine tumor cells. 61 54
17510435 2007
25
Frequency and number of neuroendocrine tumor cells in prostate cancer: no difference between radical prostatectomy specimens from patients with and without neoadjuvant hormonal therapy. 61 54
17342745 2007
26
PTHrP, calcitonin and calcitriol in a case of severe, protracted and refractory hypercalcemia due to a pancreatic neuroendocrine tumor. 54 61
17188588 2007
27
Transient receptor potential channel TRPM8 agonists stimulate calcium influx and neurotensin secretion in neuroendocrine tumor cells. 61 54
17426390 2007
28
Multinodular cutaneous spread in neuroendocrine tumor of the breast : an unusual presentation. 54 61
18039021 2007
29
Cushing's Syndrome attributable to ectopic secretion of corticotropin in a patient with two neuroendocrine tumors. 61 54
17229662 2006
30
Differential expression of alternatively spliced mRNA forms of the insulin-like growth factor 1 receptor in human neuroendocrine tumors. 54 61
16596194 2006
31
Q RT-PCR detection of chromogranin A: a new standard in the identification of neuroendocrine tumor disease. 61 54
16432362 2006
32
IFN-beta is a highly potent inhibitor of gastroenteropancreatic neuroendocrine tumor cell growth in vitro. 61 54
16397272 2006
33
[Five year remission of GHRH secreting bronchial neuroendocrine tumor with symptoms of acromegaly. Utility of chromogranin A in the monitoring of the disease]. 61 54
16575760 2006
34
Gastrinomas associated with MEN-1 syndrome: new insights for the diagnosis and management in a series of 11 patients. 54 61
16334754 2005
35
The significance of CD44 expression in gastrointestinal neuroendocrine tumors. 54 61
16001632 2005
36
Validation of commonly used immunostains on cell-transferred cytologic specimens. 61 54
15852338 2005
37
Role of gastrointestinal hormones in neuroblastoma. 61 54
15706438 2005
38
Insulin-like growth factor-1 increases intracellular calcium concentration in human primary neuroendocrine pancreatic tumor cells and a pancreatic neuroendocrine tumor cell line (BON-1) via R-type Ca2+ channels and regulates chromogranin a secretion in BON-1 cells. 54 61
16424676 2005
39
Expression of pS2 in prostate cancer correlates with grade and Chromogranin A expression but not with stage. 61 54
15588310 2004
40
Malignant gastric ghrelinoma with hyperghrelinemia. 61 54
15292299 2004
41
Practical markers used in the diagnosis of endocrine tumors. 61 54
15220821 2004
42
hASH1 expression is closely correlated with endocrine phenotype and differentiation extent in pulmonary neuroendocrine tumors. 61 54
14657947 2004
43
Subtype selective interactions of somatostatin and somatostatin analogs with sst1, sst2, and sst5 in BON-1 cells. 61 54
15456957 2004
44
Cyclical Cushing's syndrome in a patient with a bronchial neuroendocrine tumor (typical carcinoid) expressing ghrelin and growth hormone secretagogue receptors. 61 54
14671177 2003
45
R-type Ca(2+)-channel activity is associated with chromogranin A secretion in human neuroendocrine tumor BON cells. 61 54
14502430 2003
46
Medullary thyroid carcinoma and hormones. 61 54
12746649 2003
47
Neuropeptides as autocrine growth factors in cancer cells. 54 61
12570813 2003
48
Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. 61 54
12541121 2003
49
Activation of the ras/raf-1 signal transduction pathway in carcinoid tumor cells results in morphologic transdifferentiation. 54 61
12490852 2002
50
Pheochromocytoma producing vasoactive intestinal peptide. 61 54
11795252 2002

Variations for Neuroendocrine Tumor

ClinVar genetic disease variations for Neuroendocrine Tumor:

6 ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 CDKN1B NM_004064.4(CDKN1B):c.127delinsTAA (p.Arg43Ter)indel Likely pathogenic 157518 rs797044481 12:12870900-12870900 12:12717966-12717966
2 CDKN1B NM_004064.4(CDKN1B):c.279_280insT (p.Pro94fs)insertion Likely pathogenic 157519 rs797044482 12:12871052-12871053 12:12718118-12718119
3 CDKN1B NM_004064.4(CDKN1B):c.334del (p.Ser112fs)deletion Likely pathogenic 157520 rs797044483 12:12871107-12871107 12:12718173-12718173

Cosmic variations for Neuroendocrine Tumor:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM93201361 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.644G>C p.S215T 17:7674887-7674887 4

Expression for Neuroendocrine Tumor

Search GEO for disease gene expression data for Neuroendocrine Tumor.

Pathways for Neuroendocrine Tumor

Pathways related to Neuroendocrine Tumor according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.89 SYP NCAM1 MKI67 ENO2 CALCA
2 11.23 SYP NCAM1 ASCL1
3 9.64 GRP GAST CCK

GO Terms for Neuroendocrine Tumor

Cellular components related to Neuroendocrine Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.85 SST SCG2 NTS NCAM1 GRP GAST
2 secretory granule GO:0030141 9.54 SCG2 CHGB CHGA
3 terminal bouton GO:0043195 9.43 SYP CCK CALCA
4 neuronal cell body GO:0043025 9.43 SST MTOR ENO2 CCK CALCA ASCL1
5 neuronal dense core vesicle GO:0098992 9.32 SCG2 CHGA
6 extracellular space GO:0005615 9.32 SST SCG2 GRP GAST ENO2 DLK1

Biological processes related to Neuroendocrine Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 9.95 SSTR2 SST NTS GRP GAST CCK
2 cellular protein metabolic process GO:0044267 9.76 SCG2 MEN1 CHGB CALCA
3 negative regulation of protein phosphorylation GO:0001933 9.65 MTOR MEN1 INSM1
4 sympathetic ganglion development GO:0061549 9.43 INSM1 ASCL1
5 positive regulation of sensory perception of pain GO:1904058 9.37 MTOR CCK
6 type B pancreatic cell differentiation GO:0003309 9.32 MEN1 INSM1
7 positive regulation of phospholipase C-activating G protein-coupled receptor signaling pathway GO:1900738 9.26 GRP CHGA
8 neuropeptide signaling pathway GO:0007218 9.26 SSTR2 NTS GRP CALCA
9 noradrenergic neuron development GO:0003358 9.16 INSM1 ASCL1
10 adrenal chromaffin cell differentiation GO:0061104 8.62 INSM1 ASCL1

Molecular functions related to Neuroendocrine Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuropeptide hormone activity GO:0005184 9.13 NTS GRP CCK
2 hormone activity GO:0005179 9.02 SST GAST CHGB CCK CALCA

Sources for Neuroendocrine Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....